Amgen (NASDAQ:AMGN) stock in focus as company starts Phase 3 trials for obesity drug MariTide, aiming to challenge Eli Lilly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback